UroAlerts - Prostate Cancer Weekly

June 16, 2026

Videos

Peer-to-Peer Clinical Conversations

Radiopharmaceuticals in Prostate Cancer Part 4B: Payloads, Carriers, Targets, and Combinations - Michael Morris & Rana McKay

Michael J. Morris

Michael Morris and Rana McKay discuss isotope and carrier selection, combination strategies, and emerging targets in radiopharmaceutical therapy with Philip Kantoff.

Phase 2 TheraPb Trial Evaluates a Novel Induction and Maintenance Regimen of 212Pb-ADVC001 Across Three Metastatic Prostate Cancer Indications - Anna Karmann

Anna Karmann

Anna Karmann outlines AdvanCell's Lead-212 alpha-emitting radioligand therapy program, covering the phase one experience and an emerging phase two design.

Beyond the Abstracts

Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate after Radical Prostatectomy in Men with High-risk Localized Prostate Cancer - Beyond the Abstract

Personalizing Prostate Cancer Education for Patients Using an EHR-Integrated LLM Agent - Beyond the Abstract

Conference Coverage

SNMMI 2026: Predictive Value of Baseline PSMA PET Imaging Biomarkers in 177Lu-DGUL Therapy: A Phase I/II trial Sub-analysis in mCRPC

ASCO 2026: Major Adverse Cardiovascular Events in ARPI-Treated Patients with mCSPC

ASCO 2026: AMPLIFY: A Phase 3 Study of 64Cu-SAR-bisPSMA PET in Participants with Biochemical Recurrence of Prostate Cancer

AUA 2026: Behind the Scenes of Leading Urology Clinical Trials - Setting the Stage: Reflections and Advice on Finding Your Pathway to the Plenary Stage

AUA 2026: Beyond First/Second-Line mCRPC Treatment: What's Next?

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Micro-ultrasound guided versus multiparametric MRI-guided prostate biopsy: a systematic review and meta-analysis.

HSD3B1 links ileal steroid metabolism to bile acid regulation in patients with prostate cancer.

Digital pathology for repeat prostate biopsy reassessment during active surveillance: an institutional experience.

Impact of ataxia-telangiectasia mutated (ATM) loss on radiobiological and immune response to radium-223 in prostate cancer in vitro models.

PSA Response as a Prognostic Marker in Metastatic Hormone-sensitive Prostate Cancer: Comparison with Tumor Volume (CHAARTED).

Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.

Comparative real-world analysis of stereotactic body radiotherapy versus conventional radiotherapy for Chinese patients with low- to intermediate-risk localised prostate cancer.

Risk-Adapted Follow-up after Negative MRI-Targeted Biopsy in PI-RADS 3-5 Lesions: A Clinical Cohort Study with Diagnostic Stewardship Modeling - Beyond the Abstract

Mevrometostat in Advanced Prostate Cancer: Targeting EZH2 Across the Disease Continuum Through the MEVPRO Clinical Trial Program

Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate Cancer.

PSA persistence in the PSMA PET era: reassessing a risk factor after radical prostatectomy.

Phenotyping Prostate Cancer in a National Health System Using Large Language Models.

Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer.

Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches.

Expression of progranulin (GP88) protein appears as an independent prognostic factor for clinical progression in high-risk prostate cancer patients.

How Will PSMAddition Impact the Management of Prostate Cancer?

Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations.

FDA Approves Truqap Combination for PTEN-Deficient Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer

Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T therapy: dosimetry results.

Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.

Cell-free DNA in prostate cancer and treatment selection.

Water Vapor Therapy for the Management of Prostate Cancer: The VAPOR 2 Study Initial Results of Ablative Efficacy and Toxicity.

LuRa: Efficacy and Safety of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer - Beyond the Abstract

Delphi consensus on ex vivo fluorescence confocal microscopy in robot-assisted radical prostatectomy.

Real-Time Assessment of Surgical Margins During Radical Prostatectomy: A Comprehensive Review.

Proton Beam Therapy in Prostate Cancer: Clinical Evidence, Controversies and Future Directions.

The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study.

Impact of Homologous Recombination Repair Gene Mutations on Survival in Metastatic Prostate Cancer: A Real-World Analysis from an observational database.

Epigenetic and oncogenic inhibitors converge to drive a metabolic catastrophe in castration-resistant prostate cancer.

Enhanced Telehealth in Prostate Cancer.

Testosterone-Sparing Treatment Strategies for Biochemically Recurrent Prostate Cancer After Radical Prostatectomy - Beyond the Abstract

Comparison of automated bone scan indexes in patients with prostate cancer: aBSI and BONENAVI.

Salvage prostatectomy for locally recurrent prostate cancer after radiation: a narrative review of indications, outcomes, and surgical advancements.

Real-World Clinical Evaluation of S2,3PSA Test in a Prostate Biopsy Cohort With PSA Level of 4-10 ng/mL.

177Lutetium-PSMA-I&T therapy for metastatic castration-resistant prostate cancer (mCRPC): the first multicenter real-world study of 177Lu-PSMA-I&T in Brazil.

Implementing intervention mapping to tailor the evidence-based PREDIMED intervention for medically underserved prostate cancer patients.

Real-World Effectiveness and Treatment Persistence of Darolutamide, Apalutamide, and Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Study - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC